GlassScriptPhysician profile
Jason Keith Miles
NPI 1174889448
$5,665.58
in general payments reported to CMS, 2019-2025
32 companies · $2,266 in 2025
The $2,266 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $72.55 · 2023: $1,257 · 2024: $2,070 · 2025: $2,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,593.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $912.97 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $764.59 | 2020-2025 | Farxiga, Airsupra, Bevespi Aerosphere |
| Pfizer INC. | $746.02 | 2023-2025 | |
| Lilly USA, LLC | $640.45 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $389.15 | 2020-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $314.42 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $207.44 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $193.74 | 2023-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $170.35 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $138.43 | 2024-2025 | Freestyle Libre 3 |
| Corium, LLC | $126.75 | 2023-2024 | Azstarys |
| Lundbeck LLC | $108.05 | 2024-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $106.65 | 2024-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $103.53 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.89 | 2023-2025 | Jardiance |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $68.42 | 2023-2024 | Gardasil, Gardasil 9, Capvaxive |
| Dexcom, INC. | $63.76 | 2023-2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $63.30 | 2023-2025 | Eliquis |
| Sumitomo Pharma America, INC. | $58.59 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $57.10 | 2023 | |
| Astellas Pharma US INC | $54.84 | 2023-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $52.08 | 2020-2023 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $41.90 | 2024-2025 | Evkeeza |
| Xeris Pharmaceuticals, INC. | $40.50 | 2023 | Gvoke Hypopen |
| Eisai INC. | $30.22 | 2024-2025 | |
| Boston Scientific Corporation | $22.03 | 2025 | Bodyguardian |
| Abiomed | $19.42 | 2024 | Impella |
| Sanofi Pasteur INC. | $18.20 | 2023 | |
| Biogen, INC. | $18.13 | 2025 | Skyclarys |
| Idorsia Pharmaceuticals US INC | $16.73 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $15.73 | 2023 | Livalo |
| Supernus Pharmaceuticals, INC. | $14.20 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Miles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.